Literature DB >> 16054746

Correlation of maternal serum high-sensitive C-reactive protein levels with biochemical and clinical parameters in preeclampsia.

Selahattin Kumru1, Ahmet Godekmerdan, Selim Kutlu, Zeynep Ozcan.   

Abstract

OBJECTIVE: To investigate the relationship between serum high sensitive C-reactive protein (hsCRP) levels and biochemical and clinical parameters in preeclampsia (PE). STUDY
DESIGN: This cross-sectional study included 20 women with PE and 20 healthy pregnant women. They were recruited in the third trimester of pregnancy at the Firat University, Firat Medical Center, Department of Obstetric and Gynaecology in Elazig province. The standard biochemical and hematological parameters were measured by an advanced auto analyzer. Venous blood samples were collected at admission to the hospital at least 6h before delivery for measurement of hsCRP by a high sensitive immunonephelometric method.
RESULTS: Hemoglobin, serum hsCRP, creatinine, aspartat and alanine transaminase, lactate dehydrogenase, blood urea nitrogen and urine protein excretion were higher, and serum calcium levels were lower in patients with PE compared to control group values. In the preeclampsia group, correlation analysis tests showed a strong positive correlation between serum hsCRP levels and diastolic blood pressures (r=0.9, p=0.05, n=20) and urinary protein excretion (r=0.8, p=0.05, n=20), and a negative correlation between serum hsCRP and weight (r=-0.6, p=0.02, n=20) and length (r=-0.5, p=0.05, n=20) of the newborns. Serum hsCRP levels were also negatively correlated with weights (r=0.5, p=0.02, n=20) and lengths (r=0.5, p=0.05, n=20) of the newborns in the control group.
CONCLUSIONS: Serum hsCRP levels increase in women with PE. Elevated serum levels of hsCRP in preeclamptic women are correlated with clinical and biochemical parameters of PE. Determination of serum hsCRP levels may be used as a marker for the severity of PE.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16054746     DOI: 10.1016/j.ejogrb.2005.05.007

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  6 in total

1.  Does C-reactive protein predict recurrent preeclampsia?

Authors:  Hilary S Gammill; Robert W Powers; Rebecca G Clifton; J Peter Van Dorsten; Mark A Klebanoff; Marshall D Lindheimer; Baha Sibai; Mark B Landon; Menachem Miodovnik; Mitchell Dombrowski
Journal:  Hypertens Pregnancy       Date:  2010       Impact factor: 2.108

2.  Maternal Serum High-Sensitivity C-Reactive Protein (hsCRP) as a Prognostic Marker of Fetomaternal Outcome in Hypertensive Disorders of Pregnancy: A Novel Study.

Authors:  Ketav Joshi; Neema Acharya; Sourya Acharya; Samir Joshi
Journal:  Cureus       Date:  2022-04-20

3.  Inflammatory disturbances in preeclampsia: relationship between maternal and umbilical cord blood.

Authors:  Cristina Catarino; Alice Santos-Silva; Luís Belo; Petronila Rocha-Pereira; Susana Rocha; Belmiro Patrício; Alexandre Quintanilha; Irene Rebelo
Journal:  J Pregnancy       Date:  2012-05-23

4.  Determination of glucose exchange rates and permeability of erythrocyte membrane in preeclampsia and subsequent oxidative stress-related protein damage using dynamic-19F-NMR.

Authors:  Elizabeth Dickinson; John R P Arnold; Julie Fisher
Journal:  J Biomol NMR       Date:  2017-02-21       Impact factor: 2.835

5.  Actions of Esomeprazole on the Maternal Vasculature in Lean and Obese Pregnant Mice with Impaired Nitric Oxide Synthesis: A Model of Preeclampsia.

Authors:  Natasha de Alwis; Natalie K Binder; Yeukai T M Mangwiro; Sally Beard; Natasha Pritchard; Elif Kadife; Bianca R Fato; Emerson Keenan; Fiona C Brownfoot; Tu'uhevaha J Kaitu'u-Lino; Natalie J Hannan
Journal:  Int J Mol Sci       Date:  2022-07-25       Impact factor: 6.208

6.  Prognostic Value of Cardiovascular Disease Risk Factors Measured in the First-Trimester on the Severity of Preeclampsia.

Authors:  Po-Jen Cheng; Shang-Yu Huang; Sheng-Yuan Su; Ching-Hwa Hsiao; Hsiu-Huei Peng; Tao Duan
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.